Immunological and prognostic significance of tumour necrosis in colorectal cancer.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
03
11
2022
accepted:
23
03
2023
revised:
21
03
2023
medline:
7
6
2023
pubmed:
9
4
2023
entrez:
8
4
2023
Statut:
ppublish
Résumé
Colorectal cancer (CRC) causes the second most cancer deaths worldwide, but the disease course varies according to tumour characteristics and immunological factors. Our objective was to examine the associations of tumour necrosis with tumour characteristics, immune cell infiltrates, serum cytokine concentrations, as well as prognosis in CRC. Three independent CRC cohorts, including 1413 patients, were analysed. Associations of the areal percentage of tumour necrosis with clinicopathologic parameters, tumour infiltrating immune cells, cytokine concentrations in systemic and mesenteric vein blood, and survival were examined. Higher tumour necrosis percentage associated with shorter colorectal cancer-specific survival independent of tumour grade, T, N or M-class, mismatch repair status, BRAF status, and other possible confounding factors. In the largest cohort (N = 1100), the HR for high tumour necrosis percentage (≥40% vs. <3%) was 3.22 (95% CI 1.68-6.17, P Our results support the value of tumour necrosis as a prognostic factor in colorectal cancer. CXCL8 may have a role in the systemic effects of tumour necrosis.
Sections du résumé
BACKGROUND
Colorectal cancer (CRC) causes the second most cancer deaths worldwide, but the disease course varies according to tumour characteristics and immunological factors. Our objective was to examine the associations of tumour necrosis with tumour characteristics, immune cell infiltrates, serum cytokine concentrations, as well as prognosis in CRC.
METHODS
Three independent CRC cohorts, including 1413 patients, were analysed. Associations of the areal percentage of tumour necrosis with clinicopathologic parameters, tumour infiltrating immune cells, cytokine concentrations in systemic and mesenteric vein blood, and survival were examined.
RESULTS
Higher tumour necrosis percentage associated with shorter colorectal cancer-specific survival independent of tumour grade, T, N or M-class, mismatch repair status, BRAF status, and other possible confounding factors. In the largest cohort (N = 1100), the HR for high tumour necrosis percentage (≥40% vs. <3%) was 3.22 (95% CI 1.68-6.17, P
CONCLUSIONS
Our results support the value of tumour necrosis as a prognostic factor in colorectal cancer. CXCL8 may have a role in the systemic effects of tumour necrosis.
Identifiants
pubmed: 37031328
doi: 10.1038/s41416-023-02258-2
pii: 10.1038/s41416-023-02258-2
pmc: PMC10241859
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2218-2226Informations de copyright
© 2023. The Author(s).
Références
Pol J Pathol. 2020;71(3):221-228
pubmed: 33112112
Oncoimmunology. 2020 Jun 24;9(1):1783046
pubmed: 32923147
World J Gastroenterol. 2019 Aug 21;25(31):4383-4404
pubmed: 31496619
Oncol Lett. 2021 Feb;21(2):174
pubmed: 33552291
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
J Cancer Res Clin Oncol. 2016 Feb;142(2):453-63
pubmed: 26094047
Sci Rep. 2016 Apr 14;6:24552
pubmed: 27076368
J Clin Med. 2021 Apr 17;10(8):
pubmed: 33920665
Br J Cancer. 2012 May 22;106(11):1833-41
pubmed: 22617157
Hum Pathol. 2021 Jan;107:104-116
pubmed: 33161028
Virchows Arch. 2012 May;460(5):455-65
pubmed: 22527018
Br J Cancer. 2021 Feb;124(4):786-796
pubmed: 33223535
Br J Surg. 2012 Feb;99(2):287-94
pubmed: 22086662
Br J Cancer. 2016 Jun 14;114(12):1334-42
pubmed: 27195424
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Anticancer Res. 2013 Mar;33(3):1099-105
pubmed: 23482787
Ann Oncol. 2013 Jan;24(1):179-85
pubmed: 22865778
World J Gastroenterol. 2014 Jul 21;20(27):8910-20
pubmed: 25083063
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Exp Clin Cancer Res. 2019 Nov 4;38(1):449
pubmed: 31684995
Theranostics. 2021 Jan 19;11(7):3376-3391
pubmed: 33537093
Front Oncol. 2020 Nov 20;10:566430
pubmed: 33330037
Cancer Lett. 2015 May 28;361(1):22-32
pubmed: 25687885
Oxid Med Cell Longev. 2018 Jan 31;2018:3537471
pubmed: 29636841
Eur J Cancer. 2005 Nov;41(17):2645-54
pubmed: 16239109
Mod Pathol. 2017 Sep;30(9):1299-1311
pubmed: 28548122
J Natl Cancer Inst. 2016 May 12;108(8):
pubmed: 27172903
Br J Cancer. 2022 Aug;127(3):514-523
pubmed: 35449453
Clin Rev Allergy Immunol. 2020 Jun;58(3):313-325
pubmed: 31256327
Oncotarget. 2015 Nov 24;6(37):39676-91
pubmed: 26485755
Biomedicines. 2022 Aug 02;10(8):
pubmed: 36009404
Virchows Arch. 2014 Jun;464(6):637-43
pubmed: 24722974
World J Gastroenterol. 2005 Apr 14;11(14):2179-83
pubmed: 15810089
Int J Cancer. 2012 Aug 15;131(4):E463-74
pubmed: 21918979
Chin J Cancer Res. 2011 Dec;23(4):276-82
pubmed: 23358806
Br J Cancer. 2012 Nov 6;107(10):1729-36
pubmed: 23059742
Mol Cancer Res. 2014 Sep;12(9):1225-32
pubmed: 24842234
Sci Rep. 2018 Jan 18;8(1):1126
pubmed: 29348549
J Transl Med. 2019 Jun 13;17(1):199
pubmed: 31196200
Virchows Arch. 2017 May;470(5):505-515
pubmed: 28315938
Cancer Treat Rev. 2013 Feb;39(1):89-96
pubmed: 22858249
Am J Surg Pathol. 2003 May;27(5):563-70
pubmed: 12717242
Br J Cancer. 2015 Jun 9;112(12):1966-75
pubmed: 25973534
Gut. 2018 Nov;67(11):1984-1994
pubmed: 29437871
Hum Pathol. 2010 Dec;41(12):1749-57
pubmed: 20869096